Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data

Diabetes/Metabolism Research and Reviews

Volumn 33, Issue 8, 2017, Pages

  Blau, Jenny E ^a   Tella, Sri Harsha ^a   Taylor, Simeon I ^a,b   Rother, Kristina I ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

adverse event; DKA; FAERS; ketoacidosis; SGLT2 inhibitors

Indexed keywords

SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; DIABETIC PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS; FACTUAL DATABASE;

DATABASES, FACTUAL; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; KETOSIS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85030652992     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2924     Document Type: Article

References (37)

1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
3. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
4. AstraZeneca. Multicenter trial to evaluate the effect of Dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). Jan 2017; Available from: https://clinicaltrials.gov/ct2/show/NCT01730534?term=dapagliflozin+outcome&rank=6.
5. Invokana prescribing information. Available from: www.invokanahcp.com/prescribing-information.pdf.
6. Bilezikian JP, Watts NB, Usiskin K, et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with Canagliflozin. J Clin Endocrinol Metab. 2016;101(1):44-51.
7. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of Canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101(1):157-166.
8. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258-2265.
9. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the Canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;
10. (FDA), F.a.D.A, FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015.
11. (FDA), F.a.D.A, FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. December 4, 2015.
12. Endocrinologists, A.A.O, AACE/ACE scientific and clinical review: association of SGLT2 inhibitors and DKA. 2015.
13. Jensen ML, Persson F, Andersen GS, et al. Incidence of ketoacidosis in the Danish type 2 diabetes population before and after introduction of sodium-glucose cotransporter 2 inhibitors—a nationwide, retrospective cohort study, 1995-2014. Diabetes Care. 2017;40(5):e57-e58.
14. Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376(23):2300-2302.
15. Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia. 2017;
16. FDA. Drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. June 9. December 4, 2015;2016 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm
17. Boehringer-Ingelheim.com. Financial reports. July 30, 2015; Available from: https://www.boehringer-ingelheim.com/corporate_profile/annual_report.html.
18. Janssenbelgium.be. Annual report. July 30, 2015; Available from: http://www.janssenbelgium.be/en/media-center/documents/annual-report-jj-2013.
19. Lilly, E. Annual reports and financials. July 30, 2015; Available from: https://investor.lilly.com/annuals.cfm.
20. AstraZeneca.com. Financial reports. July 30, 2015; Available from: http://www.astrazeneca.com/Investors/financial-information/Financial-results.
21. Information, T.I. Financial information July 30, 2015]; Available from: https://www.takeda.com/investor-information/annual/.
22. Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D exchange clinic registry. J Clin Endocrinol Metab. 2013;98(8):3411-3419.
23. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638-1642.
24. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124(2):499-508.
25. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512-517.
26. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes. 2016;65(5):1190-1195.
27. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1-22.
28. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65
29. Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes. Diabetes Care. 2016;39(11):2036-2041.
30. Yabe D, Iwasaki M, Kuwata H, et al. SGLT2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative exploratory study. Diabetes Obes Metab. 2017;19(5):739-743.
31. Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015;17(2):188-197.
32. Dhatariya K. Comment on Erondu et al. Diabetic ketoacidosis and related events in the Canagliflozin type 2 diabetes clinical program. Diabetes care 2015;38:1680-1686. Diabetes Care. 2016;39(1):e18
33. Challenges for the FDA: The Future of Drug Safety, Workshop Summary. Washington DC, National Academy of Sciences; 2007.
34. Psaty BM, Burke SP. Protecting the health of the public—Institute of Medicine recommendations on drug safety. N Engl J Med. 2006;355(17):1753-1755.
35. Bazelier MT, Vestergaard P, Gallagher AM, et al. Risk of fracture with thiazolidinediones: disease or drugs? Calcif Tissue Int. 2012;90(6):450-457.
36. Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf. 2011;10(3):419-428.
37. Karagiannis T, Boura P, Tsapas A. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Ther Adv Drug Saf. 2014;5(3):138-146.